This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Embolism Outcomes Stroke 
Open Heart
JANUARY 31, 2025
Life-threatening complications of infective endocarditis (IE,) are heart failure, uncontrolled infection and embolic events (EE), which pose significant morbidity and mortality risks. Depending on the location and severity of the embolism, the embolic risk can either escalate or alternatively, complicate and delay cardiac surgery.
52 
CardiacWire
JANUARY 24, 2025
Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06). year follow-up. per 100 person-year.
59 
Heart BMJ
MAY 10, 2024
Objectives The use of cerebral embolic protection (CEP) during transcatheter aortic valve implantation (TAVI) has been studied in several randomised trials. We aimed to perform a systematic review and Bayesian meta-analysis of randomised CEP trials, focusing on a clinically relevant reduction in disabling stroke.
52 
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page ATP388-ATP388, February 1, 2025. Introduction:Embolic Stroke of Undetermined Source (ESUS) accounts for a critical proportion of all ischemic strokes. Disambiguating embolism etiology is important to improve treatment efficacy and reduce recurrent events.
40 
Frontiers in Cardiovascular Medicine
DECEMBER 20, 2023
Massive pulmonary embolism (MPE) carries significant 30-day mortality and is characterized by acute right ventricular failure, hypotension, and hypoxia, leading to cardiovascular collapse and cardiac arrest. Considerable heterogeneity in studies is a significant weakness of the available literature.
56 
Journal of the American Heart Association
MARCH 21, 2025
BackgroundWe aimed to reevaluate randomized controlled trial data on outcomes of cerebral embolic protection device use during transcatheter aortic valve implantation. Primary outcomes included all stroke, disabling stroke, and allcause mortality.
40 
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page AWMP98-AWMP98, February 1, 2025. Background:The use of oral anticoagulation (OAC) for stroke prevention in embolic stroke of undetermined source (ESUS) is hypothesized to be beneficial over conventional antiplatelet use. A random-effects model was used for the analyses. RevMan Web).Results:14,582
40 
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWP214-AWP214, February 1, 2024. Introduction:Middle meningeal artery embolization for chronic subdural hematomas is a promising treatment either as an adjuvant to surgical evacuation of the hematoma or as a primary treatment modality. The mean maximal diameter of the collection was 16.3 ± 6.6
40 Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page AWP251-AWP251, February 1, 2025. Middle meningeal artery (MMA) embolization is being utilized more frequently as adjunctive and primary treatment. Here, we present the outcomes of this technique with different embolic agents in our patient population.IRB approval was obtained for this study.
40 
DAIC
FEBRUARY 12, 2024
This critical information empowers physicians to select the most suitable endovascular therapeutic approach, thereby mitigating complications, avoiding embolization, and enhancing long-term treatment outcomes.
Journal of the American Heart Association
JANUARY 19, 2024
BackgroundCerebral embolic protection devices (CEPD) capture embolic material in an attempt to reduce ischemic brain injury during transcatheter aortic valve replacement. Primary clinical outcome was all‐cause stroke. Secondary clinical outcomes were disabling stroke and all‐cause mortality.
40 
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page AWMP87-AWMP87, February 1, 2024. and 4.2%, while good outcome was similar between 40% and 38%. and 0%, recurrent stroke 6.4% Purpose:The technique and efficacy of endovascular treatment (EVT) for intracranial atherosclerotic occlusion (ICAD) have not been established. Reocclusion was 3.1%
40 
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page ATP136-ATP136, February 1, 2025. Once these post-stroke patients have been identified, they are given a personalized monitoring plan depending on the individuals risk factors, the personalized care and rehabilitation plans are tracked and followed.
40 
DAIC
FEBRUARY 13, 2024
Other select data from research studies unveiled last week at the American Heart Association ’s International Stroke Conference (ISC) underscore and reinforce the pivotal role of the RapidAI platform in advancing stroke care. Improved Stroke Outcomes Following Implementation of RapidAI Platform at Ascension-Illinois, by Malisch et.
111 
Journal of the American Heart Association
FEBRUARY 14, 2025
The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety. In the matched cohort, DOAC use (versus warfarin) was associated with a lower rate of ischemic stroke or systemic embolism (HR, 0.70 [95% CI, 0.610.81]) and bleeding (HR, 0.72 [95% CI, 0.650.80]).
Stroke Journal
APRIL 2, 2025
Stroke, Ahead of Print. Clinical outcomes were measured at 1, 6, and 12 months after discharge. Radiological outcomes were measured at birth, discharge, and 3 to 9 months after discharge. Inverse probability weighting showed that the treatment effect of embolization was negligible for most outcomes.
45 
Open Heart
MAY 11, 2023
Objective There is a substantial incidence of stroke in patients with atrial fibrillation (AF) not receiving anticoagulation. The aim of our study was to investigate factors associated with patient refusal of anticoagulation and the clinical outcomes in these patients. to 1.76)) but lower all-cause mortality (aHR 0.59 (95% CI 0.43
52 
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page ATP195-ATP195, February 1, 2024. Previous studies have noted that ICAD-related LVOs, compared to embolic occlusions, have longer procedural times and lower successful reperfusion rates. However, clinical outcomes remain similar.
40 
Frontiers in Cardiovascular Medicine
DECEMBER 3, 2024
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrial fibrillation. Compared to no thrombocytopenia, atrial fibrillation patients combined with thrombocytopenia have a significant risk reduction of ischemic stroke/systemic embolism [OR: 0.79, 95% CI: (0.69, 0.91); P < 0.01].
Journal of Cardiovascular Electrophysiology
DECEMBER 23, 2024
This has been associated with poor clinical outcomes. We aim to investigate the impact of anemia on clinical outcomes in patients with AF on oral anticoagulation. However, the impact of anemia did not significantly affect the risk of stroke, transient ischemic stroke (TIA), or systemic embolism (HR: 1.07
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. The inflow aneurysms were accessed and embolized with coils using a second microcatheter prior to AVM embolization. Embolization of three posterior feeding pedicles was subsequently performed utilizing dilute NBCA.
40 
DAIC
FEBRUARY 27, 2024
Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort. Stroke is a major concern for millions of people living with atrial fibrillation, and as physicians, we strive to deliver better outcomes for these patients."
Journal of the American Heart Association
NOVEMBER 28, 2023
We searched the PubMed, EMBASE, and Cochrane databases for randomized controlled trials that compared thromboembolic or bleeding outcomes between a direct oral anticoagulant (DOAC) and a vitamin K antagonist (VKA) and reported outcomes for patients aged ≥75 years with atrial fibrillation. prospero/.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. were treated with an endovascular approach; 50% underwent onyx embolization, 28.6% underwent n‐BCA embolization, 14.2% underwent coil embolization, and 7.2% (n=1) underwent surgical intervention. Among those IIAs treated, 92.8%
40 
DAIC
MARCH 31, 2025
These results suggest that abelacimab may be safe across the spectrum of bleeding risk and may make it possible to anticoagulate some of the most vulnerable populations who otherwise would not be treated and therefore left unprotected from the risk of stroke. Data from these trials are expected in the second half of 2026.
Journal of the American Heart Association
FEBRUARY 29, 2024
BackgroundPrevious studies suggest an association between schizophrenia and stroke, but no studies have investigated stroke subtypes. Little evidence of associations with the other stroke subtypes was found. Journal of the American Heart Association, Ahead of Print.
40 
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. 3 The third‐generation iteration of the Pipeline Embolization Device (PED) incorporates Shield technology, a phosphorylcholine coating designed to reduce thrombogenicity via mimicry of native cell membranes.4
40 
Stroke Journal
JANUARY 30, 2024
Stroke, Ahead of Print. BACKGROUND:Intravenous injection of alteplase, a recombinant tPA (tissue-type plasminogen activator) as a thrombolytic agent has revolutionized ischemic stroke management. However, when associated to tPAWTlittermates, tPANullmice had similar perfusion deficits, but less severe brain infarcts.
40 
Open Heart
MARCH 1, 2024
The primary outcome was major bleeding resulting in hospitalisation based on International Classification of Diseases (ICD)-10 codes. Secondary outcomes included intracranial bleeding, gastrointestinal bleeding and other bleeding. Propensity score matching was performed, and matched cohorts were compared using Cox proportional HRs.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. We studied the effects of COA treatment with FD alone or in combination with coil embolization, based on the origin of the ophthalmic artery in‐relation to the aneurysm sac.MethodsRetrospective analysis of a prospectively collected tertiary center database.
40 Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. A prior published analysis of national trends after one year in mechanical thrombectomy use and outcomes for stroke before and after publication of the 2015 US guideline update showed improved functional outcomes and lower peri‐procedural mortality.
40 Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page AWP272-AWP272, February 1, 2025. However, there are no existing data supporting an independent relationship between cancer and atrial cardiopathy, another atrial pathology associated with increased acute ischemic stroke (AIS) risk.
40 Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. With the advancement of endovascular coil devices, aneurysm embolization with coiling is becoming the more preferred treatment approach compared to craniotomy with microsurgical clipping.
40 Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionHere, we describe a patient in whom ischemic stroke was caused by compression of the Internal Carotid Artery (ICA) by a Pseudoaneurysm (PSA) of the External Carotid Artery (ECA) after Gun Shot injury.
40 
Circulation
NOVEMBER 11, 2024
While intracardiac cardiac tumors and shunts are infrequent and typically asymptomatic, their existence can precipitate severe outcomes, including stroke, myocardial infarction and sudden death.Case Description:A 69-year-old female presented with left sided facial droop, slurred speech and left arm weakness.
40 Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. However, IVT's efficacy on stent retriever (SR) and aspiration thrombectomy (ASP) outcomes specifically remain unclear. ResultsWe included four randomized controlled trials with 1176 patients.
40 
Stroke Journal
JANUARY 30, 2025
Stroke, Volume 56, Issue Suppl_1 , Page AWP328-AWP328, February 1, 2025. Migraine with aura(MwA) is associated with an increased risk of stroke and adverse vascular outcomes compared to those with migraine without aura (MwoA). Patients with any adverse vascular outcomes before the index ECG were excluded. p < 001).
Journal of the American Heart Association
JANUARY 31, 2024
The primary outcomes were ischemic stroke, systemic embolic events, and hospitalization for major bleeding. The secondary outcomes were intracranial hemorrhage, hospitalization for gastrointestinal bleeding, all‐cause mortality, and a composite outcome. The median follow‐up duration was 2.4 1.06];P=0.11).
Stroke Journal
FEBRUARY 1, 2024
Stroke, Volume 55, Issue Suppl_1 , Page A66-A66, February 1, 2024. Introduction:Clinical practice guidelines recommend initiation of anticoagulation within 2 weeks after stroke due to atrial fibrillation (AF). Patients were randomized into one of 4 Arms: Day 3-4 from stroke onset, Day 6, Day 10, or Day 14.
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionThe Pipeline Embolization Device (PED) is commonly used for intracranial aneurysm treatment. This review and meta‐analysis aimed to assess the long‐term outcomes of PED treatment for unruptured intracranial aneurysms (UIA).MethodsA
40 Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. In addition to medical management with DAPT or anticoagulation and high intensity statin, our literature review supports endovascular or surgical interventions due to reportedly good outcomes.
40 
Stroke Journal
JANUARY 4, 2024
Stroke, Ahead of Print. Magnetic resonance imaging follow-up was obtained in 1439 patients, of whom 1358 had no symptomatic stroke during the trial period. Compared with placebo, asundexian 50 mg daily conferred a trend toward reduced risk of recurrent ischemic stroke or incident covert infarcts (hazard ratio, 0.71 [95% CI, 0.45–1.11])
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content